Endocrine Resistance in Hormone Receptor Positive Breast Cancer–From Mechanism to Therapy

Rani, A., Stebbing, J., Giamas, G. and Murphy, J.J. 2019. Endocrine Resistance in Hormone Receptor Positive Breast Cancer–From Mechanism to Therapy. Frontiers in endocrinology. 10, p. 245. doi:10.3389/fendo.2019.00245

TitleEndocrine Resistance in Hormone Receptor Positive Breast Cancer–From Mechanism to Therapy
TypeJournal article
AuthorsRani, A., Stebbing, J., Giamas, G. and Murphy, J.J.
Abstract

The importance and role of the estrogen receptor (ER) pathway has been well-documented in both breast cancer (BC) development and progression. The treatment of choice in women with metastatic breast cancer (MBC) is classically divided into a variety of endocrine therapies, 3 of the most common being: selective estrogen receptor modulators (SERM), aromatase inhibitors (AI) and selective estrogen receptor down-regulators (SERD). In a proportion of patients, resistance develops to endocrine therapy due to a sophisticated and at times redundant interference, at the molecular level between the ER and growth factor. The progression to endocrine resistance is considered to be a gradual, step-wise process. Several mechanisms have been proposed but thus far none of them can be defined as the complete explanation behind the phenomenon of endocrine resistance. Although multiple cellular, molecular and immune mechanisms have been and are being extensively studied, their individual roles are often poorly understood. In this review, we summarize current progress in our understanding of ER biology and the molecular mechanisms that predispose and determine endocrine resistance in breast cancer patients.

Article number245
JournalFrontiers in endocrinology
Journal citation10, p. 245
ISSN1664-2392
Year2019
PublisherFrontiers
Publisher's versionfendo-10-00245-2.pdf
Digital Object Identifier (DOI)doi:10.3389/fendo.2019.00245
Publication dates
Published24 May 2019
LicenseCC BY 4.0

Related outputs

PRT062607 Achieves Complete Inhibition of the Spleen Tyrosine Kinase at Tolerated Exposures Following Oral Dosing in Healthy Volunteers
Coffey, G., Rani, A., Betz, A., Pak, Y., Haberstock-Debic, H., Pandey, A., Hollenbach, S., Gretler, D.D., Mant, T., Jurcevic, S. and Sinha, U. 2017. PRT062607 Achieves Complete Inhibition of the Spleen Tyrosine Kinase at Tolerated Exposures Following Oral Dosing in Healthy Volunteers. Journal of Clinical Pharmacology . 57 (2), p. 194–210. doi:10.1002/jcph.794

HES1 in immunity and cancer
Rani, A., Greenlaw, R., Smith, R.A. and Galustian, C. 2016. HES1 in immunity and cancer. Cytokine & Growth Factor Reviews. 30, pp. 113-117. doi:10.1016/j.cytogfr.2016.03.010

STAT5 in Cancer and Immunity
Murphy, J.J. and Rani, A. 2016. STAT5 in Cancer and Immunity. Journal of Interferon & Cytokine Research. 36 (4), pp. 226-237. doi:10.1089/jir.2015.0054

Evidence for targeting of CD38 mRNA by the post-transcriptional regulator protein ZFP36L1
Murphy, J.J. 2015. Evidence for targeting of CD38 mRNA by the post-transcriptional regulator protein ZFP36L1. 4th European Congress of Immunology. Vienna 08 Sep 2015

The Notch target Hes1, is a STAT5 target gene with implications in cancer
Rani, A., Greenlaw, R., Galustian, C. and Murphy, J.J. 2015. The Notch target Hes1, is a STAT5 target gene with implications in cancer. 2015 Meeting of the ICIS in Bamberg, Germany, October 11th -14th. Bamberg, Germany Oct 2015 doi:10.1016/j.cyto.2015.08.214

Post-Transcriptional Regulation of BCL2 mRNA by the RNA-Binding Protein ZFP36L1 in Malignant B Cells
Zekavati, A., Nasir, A., Alcaraz, A., Aldrovandi, M., Marsh, P., Norton, J.D. and Murphy, J.J. 2014. Post-Transcriptional Regulation of BCL2 mRNA by the RNA-Binding Protein ZFP36L1 in Malignant B Cells. PLoS ONE. doi:10.1371/journal.pone.0102625

ZFP36L1 negatively regulates plasmacytoid differentiation of BCL1 cells by targeting BLIMP1 mRNA
Nasir, A., Norton, J.D., Baou, M., Zekavati, A., Bijlmakers, M.J., Thompson, S. and Murphy, J.J. 2012. ZFP36L1 negatively regulates plasmacytoid differentiation of BCL1 cells by targeting BLIMP1 mRNA. PLoS ONE. 7 (12), p. e52187. doi:10.1371/journal.pone.0052187

AU-rich RNA binding proteins in hematopoiesis and leukemogenesis
Baou, M., Norton, J.D. and Murphy, J.J. 2011. AU-rich RNA binding proteins in hematopoiesis and leukemogenesis. Blood. 118 (22), pp. 5732-5740. doi:10.1182/blood-2011-07-347237

Involvement of Tis11b, an AU-rich binding protein, in induction of apoptosis by rituximab in B cell chronic lymphocytic leukemia cells
Baou, M., Jewell, A.P., Muthurania, A., Wickremasinghe, R.G., Yong, K.L., Carr, R., Marsh, P. and Murphy, J.J. 2009. Involvement of Tis11b, an AU-rich binding protein, in induction of apoptosis by rituximab in B cell chronic lymphocytic leukemia cells. Leukemia. 23 (5), pp. 986-989. doi:10.1038/leu.2008.340

Post-transcriptional regulator protein ZFP36L1 targeting of Bcl-2 mRNA
Zekavati, A., Marsh, P. and Murphy, J.J. 2009. Post-transcriptional regulator protein ZFP36L1 targeting of Bcl-2 mRNA. 2nd European Congress of Immunology. Berlin, Germany 13 – 16 September 2009

Evidence for involvement of ZFP36L1 protein downregulation in differentiation of the murine BCL1 leukaemia cell line
Nasir, A., Roberts, H., Thompson, S. and Murphy, J.J. 2009. Evidence for involvement of ZFP36L1 protein downregulation in differentiation of the murine BCL1 leukaemia cell line. 2nd European Congress of Immunology. Berlin, Germany 13 – 16 September 2009

TIS11 family proteins and their roles in post-transcriptional gene regulation
Baou, M., Jewell, A.P. and Murphy, J.J. 2009. TIS11 family proteins and their roles in post-transcriptional gene regulation. Journal of Biomedicine and Biotechnology. doi:10.1155/2009/634520

Evidence for involvement of ZFP36L1 protein downregulation in differentiation of the murine BCL1 leukaemia cell line
Nasir, A., Roberts, H., Thompson, S. and Murphy, J.J. 2008. Evidence for involvement of ZFP36L1 protein downregulation in differentiation of the murine BCL1 leukaemia cell line. BSI Immunology Congress. Glasgow 17-21 November 2008

Mode of action of Rituximab in chronic lymphocytic leukaemia: activation of Tis11b, an inducer of mRNA instability and induction of apoptosis
Baou, M., Jewell, A.P., Yong, K.L. and Murphy, J.J. 2008. Mode of action of Rituximab in chronic lymphocytic leukaemia: activation of Tis11b, an inducer of mRNA instability and induction of apoptosis. in: Moreau, I.B. (ed.) Chronic lymphocytic leukemia: new research Nova Science Publishers. pp. 141-155

Permalink - https://westminsterresearch.westminster.ac.uk/item/qv86z/endocrine-resistance-in-hormone-receptor-positive-breast-cancer-from-mechanism-to-therapy


Share this
Tweet
Email